Cellectis (CLLS) Cash from Operations Growth (3y) (2018 - 2026)
Cellectis (CLLS) Cash from Operations Growth (3y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.04 Bn | 467.25 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 122.28 Bn | 115.03 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.16 Bn | 50.98 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn | 34.32% |
| 10 | Cellectis | 285.50 Mn | 99.83 Mn | - | 16.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.38% |
| Dec 31, 2025 | -87.58% |
| Sep 30, 2025 | 59.05% |
| Jun 30, 2025 | 17.63% |
| Mar 31, 2025 | 16.77% |
| Dec 31, 2024 | 86.94% |
| Sep 30, 2024 | 42.35% |
| Jun 30, 2024 | 84.73% |
| Mar 31, 2024 | 17.10% |
| Dec 31, 2023 | 72.46% |
| Sep 30, 2023 | 12.60% |
| Jun 30, 2023 | 7.88% |
| Mar 31, 2023 | -171.78% |
| Dec 31, 2022 | 32.15% |
| Sep 30, 2022 | -0.35% |
| Jun 30, 2022 | 4.55% |
| Mar 31, 2022 | -9.94% |
| Dec 31, 2021 | -0.77% |
| Sep 30, 2021 | -26.55% |
| Jun 30, 2021 | 1.13% |